The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Achillion Pharmaceuticals Inc. | COM | 00448Q201 | 4,746 | 1,279,340 | SH | DFND | 3 | 1,279,340 | 0 | 0 | |
| Agios Pharmaceuticals Inc. | COM | 00847X104 | 207,333 | 2,535,253 | SH | DFND | 3 | 2,535,253 | 0 | 0 | |
| Akcea Therapeutics, Inc. | COM | 00972L107 | 61,197 | 2,389,571 | SH | DFND | 3 | 2,389,571 | 0 | 0 | |
| Alder Biopharmaceuticals Inc. | COM | 014339105 | 28,778 | 2,266,008 | SH | DFND | 3 | 2,266,008 | 0 | 0 | |
| Alexion Pharmaceuticals Inc. | COM | 015351109 | 155,423 | 1,394,428 | SH | DFND | 2 | 1,394,428 | 0 | 0 | |
| Alnylam Pharmaceuticals Inc. | COM | 02043Q107 | 120,450 | 1,011,338 | SH | DFND | 3 | 1,011,338 | 0 | 0 | |
| Argenx SE | SPONSORED ADR | 04016X101 | 31,920 | 396,819 | SH | DFND | 3 | 396,819 | 0 | 0 | |
| AveXis, Inc. | COM | 05366U100 | 49,778 | 402,800 | SH | DFND | 3 | 402,800 | 0 | 0 | |
| Celgene Corp | COM | 151020104 | 296,561 | 3,324,298 | SH | DFND | 2 | 3,324,298 | 0 | 0 | |
| Cidara Therapeutics Inc. | COM | 171757107 | 9,181 | 2,295,272 | SH | DFND | 3 | 2,295,272 | 0 | 0 | |
| Esperion Therapeutics Inc. | COM | 29664W105 | 174,530 | 2,412,964 | SH | DFND | 3 | 2,412,964 | 0 | 0 | |
| Five Prime Therapeutics Inc. | COM | 33830X104 | 16,793 | 977,500 | SH | DFND | 3 | 977,500 | 0 | 0 | |
| Gilead Sciences Inc. | COM | 375558103 | 201,638 | 2,674,596 | SH | DFND | 1 | 2,674,596 | 0 | 0 | |
| Halozyme Therapeutics Inc. | COM | 40637H109 | 166,909 | 8,520,137 | SH | DFND | 3 | 8,520,137 | 0 | 0 | |
| Incyte Corp. | COM | 45337C102 | 308,181 | 3,698,322 | SH | DFND | 3 | 3,698,322 | 0 | 0 | |
| Intercept Pharmaceuticals Inc. | COM | 45845P108 | 33,573 | 545,719 | SH | DFND | 3 | 545,719 | 0 | 0 | |
| Intra-Cellular Therapies Inc. | COM | 46116X101 | 46,310 | 2,200,000 | SH | DFND | 3 | 2,200,000 | 0 | 0 | |
| Ionis Pharmaceuticals Inc. | COM | 462222100 | 375,400 | 8,516,334 | SH | DFND | 3 | 8,516,334 | 0 | 0 | |
| MacroGenics Inc. | COM | 556099109 | 65,426 | 2,600,412 | SH | DFND | 3 | 2,600,412 | 0 | 0 | |
| Myovant Sciences Ltd. | COM | G637AM102 | 74,613 | 3,507,882 | SH | DFND | 3 | 3,507,882 | 0 | 0 | |
| Neurocrine Biosciences Inc. | COM | 64125C109 | 282,190 | 3,402,753 | SH | DFND | 3 | 3,402,753 | 0 | 0 | |
| Novavax Inc. | COM | 670002104 | 17,493 | 8,330,000 | SH | DFND | 3 | 8,330,000 | 0 | 0 | |
| Prothena Corp. PLC | SHS | G72800108 | 14,684 | 400,000 | SH | DFND | 3 | 400,000 | 0 | 0 | |
| Radius Health Inc. | COM NEW | 750469207 | 210,386 | 5,853,799 | SH | DFND | 4 | 5,853,799 | 0 | 0 | |
| Regeneron Pharmaceuticals Inc. | COM | 75886F107 | 96,421 | 280,000 | SH | DFND | 2 | 280,000 | 0 | 0 | |
| Sage Therapeutics Inc. | COM | 78667J108 | 161,463 | 1,002,439 | SH | DFND | 3 | 1,002,439 | 0 | 0 | |
| Tesaro Inc. | COM | 881569107 | 93,124 | 1,629,743 | SH | DFND | 3 | 1,629,743 | 0 | 0 | |
| Vertex Pharmaceuticals Inc. | COM | 92532F100 | 240,468 | 1,475,445 | SH | DFND | 3 | 1,475,445 | 0 | 0 | |
| Voyager Therapeutics Inc. | COM | 92915B106 | 37,442 | 1,992,641 | SH | DFND | 3 | 1,992,641 | 0 | 0 | |
| Wave Life Sciences Ltd. | SHS | Y95308105 | 35,933 | 896,096 | SH | DFND | 3 | 896,096 | 0 | 0 | |